$1.5 B

ENTA Mkt cap, 04-Dec-2018

$206.6 M

Enanta Pharmaceuticals Revenue FY, 2018
Enanta Pharmaceuticals Net income (FY, 2018)72 M
Enanta Pharmaceuticals EBIT (FY, 2018)88.3 M
Enanta Pharmaceuticals Cash, 30-Sep-201863.9 M

Enanta Pharmaceuticals Income Statement

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Revenue

32.1m47.7m160.9m88.3m102.8m206.6m

Revenue growth, %

49%237%(45%)

R&D expense

16.8m18.7m23.2m40.5m57.5m94.9m

General and administrative expense

6.2m10.0m13.5m17.0m20.7m23.4m

Operating expense total

23.0m28.8m36.7m57.4m78.2m118.3m

Depreciation and amortization

2.1m

EBIT

9.0m19.0m124.1m30.8m24.6m88.3m

EBIT margin, %

28%40%77%35%24%43%

Interest expense

31.0k18.0k8.0k45.0k40.0k4.9m

Interest income

248.0k467.0k968.0k1.7m2.5m4.9m

Pre tax profit

19.3m125.5m32.6m26.9m93.1m

Income tax expense

15.2m(46.5m)(10.9m)(9.2m)(21.2m)

Net Income

9.6m34.4m79.0m21.7m17.7m72.0m

Enanta Pharmaceuticals Balance Sheet

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

8.9m30.7m21.7m16.6m65.7m63.9m

Accounts Receivable

808.0k1.7m15.3m12.8m10.6m67.2m

Inventories

1.6m1.6m8.3m9.2m3.5m

Current Assets

104.7m108.0m170.6m232.2m237.8m380.4m

PP&E

1.1m1.8m5.9m8.0m8.0m8.4m

Total Assets

117.0m155.4m246.0m281.3m326.6m414.2m

Accounts Payable

1.5m1.9m1.5m3.4m3.7m4.7m

Short-term debt

Current Liabilities

4.5m4.7m6.7m7.9m21.0m16.0m

Long-term debt

Total Debt

Total Liabilities

6.5m6.8m9.9m11.3m25.0m20.5m

Additional Paid-in Capital

217.7m221.6m230.0m242.1m256.2m276.5m

Retained Earnings

(107.4m)(73.0m)6.0m27.6m45.4m117.4m

Total Equity

110.5m148.7m236.2m269.9m301.7m393.7m

Financial Leverage

1.1 x1 x1 x1 x1.1 x1.1 x

Enanta Pharmaceuticals Cash Flow

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

9.6m34.4m79.0m21.7m17.7m72.0m

Depreciation and Amortization

221.0k352.0k639.0k1.7m2.1m2.5m

Accounts Receivable

241.0k(916.0k)(13.6m)2.4m2.2m(56.6m)

Inventories

(307.0k)568.0k(6.7m)(964.0k)3.5m

Accounts Payable

115.0k399.0k(543.0k)1.5m633.0k1.3m

Cash From Operating Activities

10.7m20.2m76.7m35.8m52.7m29.2m

Purchases of PP&E

(606.0k)(1.0m)(2.3m)(4.7m)(2.5m)(3.0m)

Cash From Investing Activities

(69.2m)497.0k(88.2m)(43.7m)(4.6m)(35.4m)

Cash From Financing Activities

56.9m1.2m2.5m2.7m1.0m4.4m

Interest Paid

Income Taxes Paid

148.0k40.1m12.6m1.6m26.1m

Quarterly

Enanta Pharmaceuticals Ratios

USDY, 2018

Revenue/Employee

2.3m

Financial Leverage

1.1 x
Report incorrect company information

Enanta Pharmaceuticals Employee Rating

4.54 votes
Culture & Values
4.5
Work/Life Balance
3.5
Senior Management
4.0
Salary & Benefits
4.0
Career Opportunities
4.5
Sourcewdxefcqufszuzezftuxetqsqxt